| Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer L Paz-Ares, A Luft, D Vicente, A Tafreshi, M Gümüş, J Mazières, B Hermes, ... New England Journal of Medicine 379 (21), 2040-2051, 2018 | 3109 | 2018 |
| Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... The Lancet 397 (10274), 592-604, 2021 | 549 | 2021 |
| Pembrolizumab for persistent, recurrent, or metastatic cervical cancer N Colombo, C Dubot, D Lorusso, MV Caceres, K Hasegawa, ... New England Journal of Medicine 385 (20), 1856-1867, 2021 | 536 | 2021 |
| Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ... Journal of Clinical Oncology 38 (21), 2369, 2020 | 476 | 2020 |
| Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study S Novello, DM Kowalski, A Luft, M Gümüş, D Vicente, J Mazières, ... Journal of Clinical Oncology 41 (11), 1999, 2023 | 124 | 2023 |
| Outcome of non-metastatic male breast cancer: 118 patients ÜY Arslan, B Öksüzoğlu, N Özdemir, S Aksoy, N Alkış, A Gök, MA Kaplan, ... Medical Oncology 29, 554-560, 2012 | 87 | 2012 |
| Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non–small-cell lung cancer J Mazieres, D Kowalski, A Luft, D Vicente, A Tafreshi, M Gümüş, ... Journal of Clinical Oncology 38 (3), 271-280, 2020 | 71 | 2020 |
| Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report B Aygen, AM Demir, M Gümüş, O Karabay, S Kaymakoğlu, AŞ Köksal, ... The Turkish Journal of Gastroenterology 29 (3), 259, 2018 | 46 | 2018 |
| LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... Annals of Oncology 31, S1182-S1183, 2020 | 37 | 2020 |
| Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study AI Yasin, SG Aydin, B Sümbül, L Koral, M Şimşek, Ç Geredeli, A Öztürk, ... Future Oncology 18 (10), 1235-1244, 2022 | 34 | 2022 |
| The utility of serum tumor markers CEA and CA 15–3 for breast cancer prognosis and their association with clinicopathological parameters MM Uygur, M Gümüş Cancer Treatment and Research Communications 28, 100402, 2021 | 30 | 2021 |
| The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker ME Yıldırım, U Kefeli, D Aydın, N Sener, M Gümüş Tumor Biology 37, 11903-11907, 2016 | 24 | 2016 |
| The association of serum adiponectin levels with histopathological variables in gastric cancer patients M Seker, A Bilici, B Sonmez, BBO Ustaalioğlu, M Gumus, H Gozu, ... Medical Oncology 27, 1319-1323, 2010 | 23 | 2010 |
| Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients M Ozcelik, T Korkmaz, H Odabas, C Gemici, O Ercelep, S Yuksel, AG Mert, ... Tumor Biology 37 (7), 8901-8907, 2016 | 18 | 2016 |
| Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the Anatolian Society of Medical Oncology A Bilici, M Inanc, A Ulas, T Akman, M Seker, N Babacan, A Inal, O Bal, ... Asian Pacific Journal of Cancer Prevention 14 (11), 2013 | 18 | 2013 |
| Pulmonary BALT lymphoma successfully treated with eight cycles weekly rituximab: report of first case and F-18 FDG PET/CT images A Bilici, M Seker, BBO Ustaalioglu, N Canpolat, T Salepci, M Gumus Journal of Korean Medical Science 26 (4), 574, 2011 | 18 | 2011 |
| Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO) D Aydın, MA Şendur, U Kefeli, OU Ünal, D Taştekin, M Akyol, E Tanrıkulu, ... Journal Of Buon, 2016 | 17 | 2016 |
| Treatment modalities in primary gastric lymphoma: effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology K Mehmet, C Sener, U Uyeturk, M Seker, D Tastekin, O Tonyali, ... Contemporary Oncology/Współczesna Onkologia 18 (4), 273-278, 2014 | 16 | 2014 |
| Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826 … BJ Monk, KS Tewari, C Dubot, MV Caceres, K Hasegawa, ... The lancet oncology 24 (4), 392-402, 2023 | 15 | 2023 |
| Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast M Seker, A Bilici, BO Ustaalioglu, B Yilmaz, B Ozturk, A Ünal, F Dane, ... Archives of gynecology and obstetrics 284, 405-409, 2011 | 15 | 2011 |
Veli BerkKayseri Memorial Hastanesimemorial.com.tr üzerinde doğrulanmış e-posta adresine sahip
